Dickinson AM, Norden J, Li S, Hromadnikova I, Schmid C, Schmetzer H, et al. Graft-versus-Leukemia effect following hematopoietic stem cell transplantation for leukemia. Front Immunol. 2017;8:496.

PubMed  PubMed Central  Google Scholar 

Sauerer T, Velázquez GF, Schmid C. Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy. Mol Cancer. 2023;22(1):180.

PubMed  PubMed Central  Google Scholar 

Kreidieh F, Abou Dalle I, Moukalled N, El-Cheikh J, Brissot E, Mohty M, et al. Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment. Int J Hematol. 2022;116(3):330–40.

CAS  PubMed  Google Scholar 

Merryman RW, Armand P. Immune checkpoint Blockade and hematopoietic stem cell transplant. Curr Hematol Malig Rep. 2017;12(1):44–50.

PubMed  Google Scholar 

Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med. 2016;375(2):143–53.

CAS  PubMed  PubMed Central  Google Scholar 

Cai L, Li Y, Tan J, Xu L, Li Y. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16(1):101.

CAS  PubMed  PubMed Central  Google Scholar 

Sauer N, Janicka N, Szlasa W, Skinderowicz B, Kołodzińska K, Dwernicka W, et al. TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors. Cancer Immunol Immunother. 2023;72(11):3405–25.

CAS  PubMed  PubMed Central  Google Scholar 

Lee JB, Vasic D, Kang H, Fang KK, Zhang L. State-of-Art of cellular therapy for acute leukemia. Int J Mol Sci. 2021;22(9).

Lee JB, Kang H, Fang L, D’Souza C, Adeyi O, Zhang L. Developing allogeneic Double-Negative T cells as a novel Off-the-Shelf adoptive cellular therapy for cancer. Clin Cancer Res. 2019;25(7):2241–53.

CAS  PubMed  Google Scholar 

Tang B, Lee JB, Cheng S, Pan T, Yao W, Wang D, et al. Allogeneic double-negative T cell therapy for relapsed acute myeloid leukemia patients post allogeneic hematopoietic stem cell transplantation: A first-in-human phase I study. Am J Hematol. 2022;97(7):E264–7.

PubMed  Google Scholar 

Vasic D, Lee JB, Leung Y, Khatri I, Na Y, Abate-Daga D, et al. Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities. Sci Immunol. 2022;7(70):eabl3642.

CAS  PubMed  Google Scholar 

Peter ME, Hadji A, Murmann AE, Brockway S, Putzbach W, Pattanayak A, et al. The role of CD95 and CD95 ligand in cancer. Cell Death Differ. 2015;22(5):885–6.

CAS  PubMed  PubMed Central  Google Scholar 

Wu Z, Zheng Y, Sheng J, Han Y, Yang Y, Pan H, et al. CD3(+)CD4(-)CD8(-) (Double-Negative) T cells in inflammation, immune disorders and cancer. Front Immunol. 2022;13:816005.

CAS  PubMed  PubMed Central  Google Scholar 

Lee J, Minden MD, Chen WHC, Streck E, Chen B, Kang H, et al. Allogeneic human double negative T cells as a novel immunotherapy for acute myeloid leukemia and its underlying mechanisms. Clin Cancer Res. 2018;24(2):370–82.

CAS  PubMed  Google Scholar 

Cuadrado E, van den Biggelaar M, de Kivit S, Chen YY, Slot M, Doubal I, et al. Proteomic analyses of human regulatory T cells reveal adaptations in signaling pathways that protect cellular identity. Immunity. 2018;48(5):1046–e596.

CAS  PubMed  Google Scholar 

Banerjee H, Nieves-Rosado H, Kulkarni A, Murter B, McGrath KV, Chandran UR, et al. Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment. Cell Rep. 2021;36(11):109699.

CAS  PubMed  PubMed Central  Google Scholar 

Chen J, Hu P, Wu G, Zhou H. Antipancreatic cancer effect of DNT cells and the underlying mechanism. Pancreatology. 2019;19(1):105–13.

CAS  PubMed  Google Scholar 

Yang L, Zhu Y, Tian D, Wang S, Guo J, Sun G, et al. Transcriptome landscape of double negative T cells by single-cell RNA sequencing. J Autoimmun. 2021;121:102653.

CAS  PubMed  Google Scholar 

Talvard-Balland N, Braun LM, Dixon KO, Zwick M, Engel H, Hartmann A, et al. Oncogene-induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in mice. J Clin Invest. 2024;134(16):e177460.

CAS  PubMed  PubMed Central  Google Scholar